Work

Abstract 5455: TAVO605, a novel CD318 (CDCP1) ADC, for the treatment of solid cancers that are non-responding or resistant to Enhertu treatment

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-5455

Authors: Guangmao Mu, Fulai Zhou, Honglei Bi, Zhengxia Zha, Sheng Huang, Ying Jin, Mingcan Yu, Chao Han, Mark Chiu, Di Zhang

Institutions: Highlight Therapeutics (Spain), Bioarray Genetics (United States), TauRx (United Kingdom)

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409632287

Cites:

Cited by:

Related to: 10